Is Axsome Therapeutics Stock a Good Investment?
Axsome Therapeutics Investment Advice | AXSM |
- Examine Axsome Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Axsome Therapeutics' leadership team and their track record. Good management can help Axsome Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Axsome Therapeutics' business and its evolving consumer preferences.
- Compare Axsome Therapeutics' performance and market position to its competitors. Analyze how Axsome Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Axsome Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Axsome Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Axsome Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Axsome Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Modest | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Axsome Therapeutics Stock
Researching Axsome Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company shares are held by company insiders. The company recorded a loss per share of 6.58. Axsome Therapeutics had not issued any dividends in recent years.
To determine if Axsome Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Axsome Therapeutics' research are outlined below:
| The company reported the previous year's revenue of 270.6 M. Net Loss for the year was (239.24 M) with profit before overhead, payroll, taxes, and interest of 45.94 M. | |
| Axsome Therapeutics currently holds about 73.39 M in cash with (145.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82. | |
| Axsome Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 81.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Axsome Therapeutics Research Analysts Recent Ratings Changes |
Axsome Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Axsome Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Axsome Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Axsome Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Axsome Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-08-08 | 2018-06-30 | -0.29 | -0.32 | -0.03 | 10 | ||
2016-05-11 | 2016-03-31 | -0.28 | -0.31 | -0.03 | 10 | ||
2017-08-09 | 2017-06-30 | -0.34 | -0.3 | 0.04 | 11 | ||
2017-11-08 | 2017-09-30 | -0.34 | -0.27 | 0.07 | 20 | ||
2019-08-08 | 2019-06-30 | -0.33 | -0.41 | -0.08 | 24 | ||
2021-05-10 | 2021-03-31 | -0.87 | -0.78 | 0.09 | 10 | ||
2018-05-08 | 2018-03-31 | -0.28 | -0.19 | 0.09 | 32 | ||
2021-08-09 | 2021-06-30 | -0.96 | -0.86 | 0.1 | 10 |
Know Axsome Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Axsome Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Axsome Therapeutics backward and forwards among themselves. Axsome Therapeutics' institutional investor refers to the entity that pools money to purchase Axsome Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deep Track Capital, Lp | 2024-09-30 | 857.2 K | Eventide Asset Management, Llc | 2024-09-30 | 827.9 K | Perceptive Advisors Llc | 2024-09-30 | 782.8 K | Wellington Management Company Llp | 2024-09-30 | 742.7 K | Alethea Capital Management, Llc | 2024-09-30 | 738.5 K | Amvescap Plc. | 2024-09-30 | 625.2 K | Hood River Capital Management Llc | 2024-09-30 | 625.1 K | Point72 Asset Management, L.p. | 2024-09-30 | 542.6 K | Adage Capital Partners Gp Llc | 2024-09-30 | 525 K | Rtw Investments, Llc | 2024-09-30 | 4.2 M | Vanguard Group Inc | 2024-09-30 | 4 M |
Axsome Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.83 B.Market Cap |
|
Axsome Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.52) | (0.54) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (1.25) | (1.19) |
Determining Axsome Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Axsome Therapeutics is a good buy. For example, gross profit margin measures Axsome Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Axsome Therapeutics' profitability and make more informed investment decisions.
Axsome Therapeutics' Earnings Breakdown by Geography
Evaluate Axsome Therapeutics' management efficiency
Axsome Therapeutics has return on total asset (ROA) of (0.2644) % which means that it has lost $0.2644 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7161) %, meaning that it created substantial loss on money invested by shareholders. Axsome Therapeutics' management efficiency ratios could be used to measure how well Axsome Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Tangible Assets is likely to drop to -0.48. In addition to that, Return On Capital Employed is likely to drop to -0.54. At this time, Axsome Therapeutics' Other Assets are very stable compared to the past year. As of the 2nd of December 2024, Intangibles To Total Assets is likely to grow to 0.18, while Return On Tangible Assets are likely to drop (0.48).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.20 | 4.41 | |
| Tangible Book Value Per Share | 2.77 | 2.90 | |
| Enterprise Value Over EBITDA | (15.18) | (15.94) | |
| Price Book Value Ratio | 18.93 | 19.88 | |
| Enterprise Value Multiple | (15.18) | (15.94) | |
| Price Fair Value | 18.93 | 19.88 | |
| Enterprise Value | 3.4 B | 3.6 B |
Leadership at Axsome Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 1.252 |
Basic technical analysis of Axsome Stock
As of the 2nd of December, Axsome Therapeutics shows the Mean Deviation of 1.78, risk adjusted performance of 0.0653, and Downside Deviation of 2.01. Axsome Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Axsome Therapeutics standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Axsome Therapeutics is priced correctly, providing market reflects its regular price of 99.08 per share. Given that Axsome Therapeutics has jensen alpha of 0.1091, we suggest you to validate Axsome Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.Axsome Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Axsome Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Axsome Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Axsome Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Axsome Therapeutics' Outstanding Corporate Bonds
Axsome Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Axsome Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Axsome bonds can be classified according to their maturity, which is the date when Axsome Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US05464HAB69 Corp BondUS05464HAB69 | View | |
| AXIS SPECIALTY FIN Corp BondUS05464HAC43 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US05463HAB78 Corp BondUS05463HAB78 | View | |
| US05463HAC51 Corp BondUS05463HAC51 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AYDEMT 775 02 FEB 27 Corp BondUS054644AA72 | View |
Understand Axsome Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Axsome Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0653 | |||
| Market Risk Adjusted Performance | 0.3371 | |||
| Mean Deviation | 1.78 | |||
| Semi Deviation | 1.87 | |||
| Downside Deviation | 2.01 | |||
| Coefficient Of Variation | 1309.82 | |||
| Standard Deviation | 2.47 | |||
| Variance | 6.12 | |||
| Information Ratio | 0.0207 | |||
| Jensen Alpha | 0.1091 | |||
| Total Risk Alpha | (0.23) | |||
| Sortino Ratio | 0.0255 | |||
| Treynor Ratio | 0.3271 | |||
| Maximum Drawdown | 13.67 | |||
| Value At Risk | (3.78) | |||
| Potential Upside | 4.1 | |||
| Downside Variance | 4.03 | |||
| Semi Variance | 3.5 | |||
| Expected Short fall | (2.21) | |||
| Skewness | 0.9524 | |||
| Kurtosis | 2.49 |
| Risk Adjusted Performance | 0.0653 | |||
| Market Risk Adjusted Performance | 0.3371 | |||
| Mean Deviation | 1.78 | |||
| Semi Deviation | 1.87 | |||
| Downside Deviation | 2.01 | |||
| Coefficient Of Variation | 1309.82 | |||
| Standard Deviation | 2.47 | |||
| Variance | 6.12 | |||
| Information Ratio | 0.0207 | |||
| Jensen Alpha | 0.1091 | |||
| Total Risk Alpha | (0.23) | |||
| Sortino Ratio | 0.0255 | |||
| Treynor Ratio | 0.3271 | |||
| Maximum Drawdown | 13.67 | |||
| Value At Risk | (3.78) | |||
| Potential Upside | 4.1 | |||
| Downside Variance | 4.03 | |||
| Semi Variance | 3.5 | |||
| Expected Short fall | (2.21) | |||
| Skewness | 0.9524 | |||
| Kurtosis | 2.49 |
Consider Axsome Therapeutics' intraday indicators
Axsome Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Axsome Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 21693.01 | |||
| Daily Balance Of Power | 0.1752 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 99.21 | |||
| Day Typical Price | 99.16 | |||
| Price Action Indicator | 0.3 | |||
| Period Momentum Indicator | 0.86 |
Axsome Therapeutics Corporate Filings
8K | 26th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F3 | 24th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Axsome Stock media impact
Far too much social signal, news, headlines, and media speculation about Axsome Therapeutics that are available to investors today. That information is available publicly through Axsome media outlets and privately through word of mouth or via Axsome internal channels. However, regardless of the origin, that massive amount of Axsome data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Axsome Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Axsome Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Axsome Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Axsome Therapeutics alpha.
Axsome Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Axsome Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Axsome Therapeutics Historical Investor Sentiment
Investor biases related to Axsome Therapeutics' public news can be used to forecast risks associated with an investment in Axsome. The trend in average sentiment can be used to explain how an investor holding Axsome can time the market purely based on public headlines and social activities around Axsome Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Axsome Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Axsome Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Axsome Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Axsome Therapeutics.
Axsome Therapeutics Corporate Management
| Hunter Esq | General Secretary | Profile | |
| Amanda PharmD | Senior Development | Profile | |
| Lori MBA | Executive Development | Profile | |
| Kevin PharmD | Ex Strategy | Profile | |
| Mark MA | Chief Officer | Profile |
Already Invested in Axsome Therapeutics?
The danger of trading Axsome Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Axsome Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Axsome Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Axsome Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.58) | Revenue Per Share 7.108 | Quarterly Revenue Growth 0.813 | Return On Assets (0.26) | Return On Equity (1.72) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Axsome Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.